Navigation Links
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Date:11/15/2007

with the PARP inhibitor BSI-201," said Joyce O'Shaughnessy, M.D., lead investigator, Texas Oncology, PA, Baylor-Sammons Cancer Center in Dallas, US Oncology, and co-chair of the breast cancer research committee of the US Oncology Research Network. "There is a compelling need for a novel approach to treating this high-risk population."

The Phase 2 trial of BSI-201 in patients with triple-negative breast cancer will enroll 120 women in a multicenter, randomized, open-label trial that will compare standard chemotherapy with or without the addition of BSI- 201.

The research presented in Brussels showed the results of an analysis of PARP gene expression in 169 infiltrating ductal breast cancers through the use of the Gene Logic Inc. (Nasdaq: GLGC) BioExpress(R) System database. PARP expression was above the 99.9 percent upper confidence limit for normal tissue in 45 percent of all breast tumors, compared with 75 percent of breast tumors that were estrogen-negative and progesterone-negative and 90 percent of HER2- negative patients.

PARP is a well-characterized and validated target for cancer therapies. PARP plays a central role in cell proliferation in DNA repair, and the PARP-1 gene is upregulated in certain tumor types.

BiPar's novel, proprietary PARP inhibitors are a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical and early clinical studies suggest the drugs selectively induce tumor cell death and are active against a broad range of tumor types. In addition to the trial in patients with triple-negative breast cancer, BiPar plans to begin a series Phase1b and Phase 2 trials of BSI-201 in other major cancers that overexpress PARP over the next
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Enrollment Begins on Human PK Study for Medidur(TM) FA
7. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
11. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 The ... statement regarding the Medicare Part D offsets included ... Cures initiative: "If the 21st Century Cures ... from America,s premier health program – Medicare – ... may yield down the road. "Leveraging ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ ... von Arzneimittelfälschungen - Zwecks Leistungsvergleich zur ... wird auf EG-Mitgliedstaaten verwiesen, in denen ... werden.  Wählen Sie ein Aegate-Land: beispielsweise ... Richtlinie zur Bekämpfung von Arzneimittelfälschungen (FMD) ...
(Date:5/21/2015)... , May 21, 2015 In praising ... Cures legislation by the House Energy and Commerce ... the Committee for recognizing the unique challenges facing ... for including bill language exempting Part D beneficiaries ... a proposed medication management "lock-in" provision. The SCPC ...
Breaking Medicine Technology:EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3SCPC Applauds Unanimous House Panel Passage of 21st Century Cures Bill Recognizing Unique Challenges Facing Long Term Care (LTC) Pharmacy Patients, Providers 2
... Pa., Dec. 7, 2011 /PRNewswire-iReach/ -- ... designing and delivering innovative solutions in Medical and ... release of Acecide ® -C, a new, peracetic ... use in the Olympus Endoscope Reprocessor, the OER-Pro, ...
... from the MarginProbe pivotal study were presented today ... Symposium.  The results were presented by Dr. Freya ... Center, New York University, New York, New York.  ... of MarginProbe significantly improved surgical outcomes by improving ...
Cached Medicine Technology:Olympus Introduces New Peracetic Acid Solution for Rapid High-Level Disinfection 2Olympus Introduces New Peracetic Acid Solution for Rapid High-Level Disinfection 3MarginProbe® Pivotal Study Presented at San Antonio Breast Cancer Symposium 2
(Date:5/22/2015)... Mountain Point Medical Center, a campus of ... on Friday, May 29, 2015 at 11 a.m., followed by ... new medical center, set to officially open on June 1, ... 84043. , “The opening of Mountain Point Medical Center ... County community,” said Kent Loosle, CEO of Mountain Point Medical ...
(Date:5/22/2015)... 22, 2015 Omar Ahmad Barrada, a ... participate in the 2015 Congress of Future Medical Leaders ... a gathering of “America’s highest achieving high school students.” ... healthcare, set new goals and learn better study habits,” ... surgery, during which we can ask the surgeons questions.” ...
(Date:5/22/2015)... 22, 2015 Family, friends, students, colleagues, ... surgical oncologist, Dr. LaSalle D. Leffall, on Monday, May ... began after Grand Rounds in the hospital’s Tower Auditorium. ... outside the auditorium, trying to keep the secret. “I’d ... he sees me, he’ll know something is up,” she ...
(Date:5/22/2015)... 2015 According to a new Aegis Living ... equally as likely to worry about what will happen to ... 77% Boomers, 69% Silent Generation), which may help explain why ... of aging, particularly Millennials (47%), Gen X’ers (51%), and Boomers ... April, 2015 among more than 2,000 U.S. adults ages 18+. ...
(Date:5/22/2015)... According to Berks and Beyond , Pennsylvania ... totaling almost 2,500 confirmed drug deaths, as reported on May ... 2,489 deaths stemming from legal and illegal drug use in ... every day to fatal overdoses or other drug related deaths. ... of the most rife with drug related deaths. The city, ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2
... - Aspreva Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ... the Investment Canada Act, has approved the acquisition ... wholly-owned Canadian,subsidiary at a price of US$26.00 per ... being carried out by way of a statutory ...
... FRIDAY, Dec. 21 (HealthDay News) -- Screening tests for ... U.S. women cost about $150 annually per woman screened, ... cost per woman each year, including administrative, quality assurance, ... analysis of the National Breast and Cervical Cancer Early ...
... Medical,Technologies, Inc. (Nasdaq: PMTI ), a leading ... today announced an agreement,with The Gillette Company (a ... (NYSE: PG )) to extend the Launch ... women until no later than February 29,2008. Under ...
... indications than any other ... drug-eluting stent, ... announced today that its TAXUS(R) Liberte(TM),paclitaxel-eluting coronary stent system has received ... submitted,data showing the TAXUS Liberte stent has benefited diabetic patients with,coronary ...
... GLENDALE, Calif., Dec. 21 The California Nurses,Association/National ... failing to approve a liver transplant one week ... night just hours,after CIGNA relented and agreed to ... Dec. 11, four leading physicians, including the surgical ...
... Dec. 21 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ) ... present a company update at the JPMorgan,26th Annual Healthcare ... on,Wednesday, January 9, 2008. The live event webcast may ... replay will be available approximately 24,hours after the presentation ...
Cached Medicine News:Health News:Aspreva receives Investment Canada approval for acquisition by Galenica 2Health News:Aspreva receives Investment Canada approval for acquisition by Galenica 3Health News:Aspreva receives Investment Canada approval for acquisition by Galenica 4Health News:Low-Income Women's Cancer Screenings Cost Effective: Report 2Health News:Low-Income Women's Cancer Screenings Cost Effective: Report 3Health News:Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms 2Health News:Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms 3Health News:Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms 4Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 2Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 4Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 5Health News:RN's Statement on Death of Nataline Sarkisyan: 'CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago' 2
...
... a semi-rigid system intended for anterior ... is based on the comprehensive, clinically ... technology. The Slim-LOC system offers maximum ... width (16 mm), low profile (2.1 ...
... Osmium is a cervical plate system ... spine. The implant provides for the ... the bone transplant has consolidated. Optimized ... and bicortical fixation. Maximum purchase also ...
... is designed to meet the clinical challenges ... attached locking mechanism and the choice of ... variable angle screws for ease of implantation ... plate system allows the surgeon the versatility ...
Medicine Products: